<DOC>
	<DOCNO>NCT00619593</DOCNO>
	<brief_summary>The MADIT-II trial show patient severely reduce leave ventricular ejection fraction ( LVEF ) post myocardial infarction benefit implantable cardioverter-defibrillator ( ICD ) . However , retrospective analysis MADIT-II data reveal significantly increase morbidity mortality patient appropriate ICD therapy : Appropriate ICD therapy associate 3.3-fold increased all-cause mortality , risk first heart failure hospitalization 90 % high 1st appropriate ICD therapy . Hence , 1st appropriate therapy might indicate necessity utility clinical diagnostics therapy patient . This trial design ( ) improve knowledge group characteristic patient suffer 1st appropriate ICD therapy , ( ii ) moreover take additional therapeutic step reduce mortality patient population .</brief_summary>
	<brief_title>Survival Patients With Primary Prophylactic ICD Indication</brief_title>
	<detailed_description>The MADIT-II trial show patient severely reduce leave ventricular ejection fraction ( LVEF ) post myocardial infarction benefit implantable cardioverter-defibrillator ( ICD ) . However , retrospective analysis MADIT-II data reveal significantly increase morbidity mortality patient appropriate ICD therapy : Appropriate ICD therapy associate 3.3-fold increased all-cause mortality , risk first heart failure hospitalization 90 % high 1st appropriate ICD therapy . Hence , 1st appropriate therapy might indicate necessity utility clinical diagnostics therapy patient . This trial design ( ) improve knowledge group characteristic patient suffer 1st appropriate ICD therapy , ( ii ) moreover take additional therapeutic step reduce mortality patient population . After standard ICD implantation procedure , follow step perform pre-discharge follow-up : - Programming : VR-T : VVI 40 ppm , Onset 20 % , Stability 20 m - DR-T : DDD 50-60 ppm , activation IRSplus SMART - HF-T : DDD-BiV 50-60 ppm , achieve least 85 % biventricular resynchronisation , activation SMART - All device : VT zone therapy zone , VF zone . Programming recommendation VT/VF zone standardize treatment : - VF zone : 200-250 bpm/ 300-240 m , ATPoneshot ON - VT1 zone : 167-200 bpm/ 360-300 m , ATP ON - VT2 zone : 120-167 bpm/ 500-360 m , ATP ON - Activation Home Monitoring ( HM ) online registration HM service Standard Follow-up : Timing scope follow-up patient without episode physician 's discretion follow standard clinical routine . Follow-up 1st appropriate ICD therapy : Immediately receive 1st appropriate ICD therapy , patient call clinic intensified clinical diagnostics , necessary useful , intensified therapy . Standard ICD follow-up start within 72 hour 1st appropriate ICD therapy . - ICD interrogation - General health status ( weight , BP , NYHA ) - Laboratory test ( hemoglobin , Nt-proBNP , creatinine , GDF-15 ) - Echocardiography ( LVEF , LVEDD , mitral regurgitation ) - Non-invasive ischemia evaluation - Coronary angiography ( indicated ischemia evaluation ) - Upgrade CRT , indicate - Ventricular ablation ( indicate : VT storm , slow VT , bundle branch reentry ) - 24 hr ECG Holter ( Heart rate variability ) - Further treatment ( applicable ) - Changes ICD setting , medication - Adverse event / adverse device effect Final follow-up visit : For patient without appropriate ICD therapy , final follow-up shall perform 12 month enrolment . For patient appropriate ICD therapy , final follow-up shall perform 12 month 1st appropriate ICD therapy . The final follow-up visit comprises : - ICD interrogation - General health status ( weight , BP , NYHA ) - Echocardiography ( LVEF , LVEDD , mitral regurgitation ) - Laboratory test ( hemoglobin , Nt-proBNP , creatinine , GDF-15 ) - 24 hr ECG Holter ( Heart rate variability ) - Further treatment ( applicable ) - Changes ICD setting , medication - Adverse event / adverse device effect</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Indication ICD implantation accord MADITII : Myocardial infarction 30 day implantation LVEF 30 % less within 3 month implantation Angiography within precede 12 month The patient willing able comply clinical investigation plan provide write informed consent Patients contraindication ICD implantation Conventional ICD indication ( i.e . MADITII ) Myocardial infarction within past 30 day Coronary revascularisation within precede 3 month ( i.e. , revascularization perform wait least 3 month enrolment , give appropriate/ inappropriate ICD therapy occur ) NYHA functional class IV Unexplained syncope within 3 year Advanced cerebrovascular disease Life expectancy probably 12 month Pregnant breastfeed woman Age &lt; 18 year Patients already enrol another study ( therapy/intervention phase )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Ventricular Fibrillation</keyword>
	<keyword>Sudden cardiac death</keyword>
	<keyword>Hospitalization due heart failure</keyword>
	<keyword>Implantable cardioverter-defibrillator</keyword>
	<keyword>Risk 1st heart failure hospitalization</keyword>
</DOC>